Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

3343 results about "Dopamine" patented technology

Dopamine (DA, a contraction of 3,4-dihydroxyphenethylamine) is an organic chemical of the catecholamine and phenethylamine families. It functions both as a hormone and a neurotransmitter, and plays several important roles in the brain and body. It is an amine synthesized by removing a carboxyl group from a molecule of its precursor chemical L-DOPA, which is synthesized in the brain and kidneys. Dopamine is also synthesized in plants and most animals. In the brain, dopamine functions as a neurotransmitter—a chemical released by neurons (nerve cells) to send signals to other nerve cells. The brain includes several distinct dopamine pathways, one of which plays a major role in the motivational component of reward-motivated behavior. The anticipation of most types of rewards increases the level of dopamine in the brain, and many addictive drugs increase dopamine release or block its reuptake into neurons following release. Other brain dopamine pathways are involved in motor control and in controlling the release of various hormones. These pathways and cell groups form a dopamine system which is neuromodulatory.

Sensors for detecting substances indicative of stroke, ischemia, or myocardial infarction

ActiveUS20060079740A1Thickness minimizationTransport of glucose to the sensor is not altered over timeStentsCatheterMetaboliteCitrulline
A sensor is disclosed, for implantation within a blood vessel to monitor a substance in or property of blood. In one embodiment, the sensor detects nitric oxide or a nitric oxide metabolite. In another embodiment, other substances such as glutamate, aspartate, arginine, citrulline, acetylcholine, calcium, potassium, or dopamine are monitored. The sensor may be attached to a support structure such as a stent, guidewire, or catheter. In a further embodiment, a catheter is disclosed that extracts patient fluid to a sensor outside the body for monitoring a substance or property of the patient fluid. Methods are also disclosed.
Owner:SILVER JAMES H +1

Matrices for drug delivery and methods for making and using the same

In one aspect, biocompatible matrices such as sol-gels encapsulating a reaction center may be administered to a subject for conversion of prodrugs into biologically active agents. In certain embodiments, the biocompatible matrices of the present invention are sol-gels. In one embodiment, the enzyme <SMALLCAPS>L< / SMALLCAPS>-amino acid decarboxylase is encapsulated and implanted in the brain to convert <SMALLCAPS>L< / SMALLCAPS>-dopa to dopamine for treatment of Parkinson's disease.
Owner:MOLECULAR INSIGHT PHARMA

Solving the distal reward problem through linkage of stdp and dopamine signaling

In Pavlovian and instrumental conditioning, rewards typically come seconds after reward-triggering actions, creating an explanatory conundrum known as the distal reward problem or the credit assignment problem. How does the brain know what firing patterns of what neurons are responsible for the reward if (1) the firing patterns are no longer there when the reward arrives and (2) most neurons and synapses are active during the waiting period to the reward? A model network and computer simulation of cortical spiking neurons with spike-timing-dependent plasticity (STDP) modulated by dopamine (DA) is disclosed to answer this question. STDP is triggered by nearly-coincident firing patterns of a presynaptic neuron and a postsynaptic neuron on a millisecond time scale, with slow kinetics of subsequent synaptic plasticity being sensitive to changes in the extracellular dopamine DA concentration during the critical period of a few seconds after the nearly-coincident firing patterns. Random neuronal firings during the waiting period leading to the reward do not affect STDP, and hence make the neural network insensitive to this ongoing random firing activity. The importance of precise firing patterns in brain dynamics and the use of a global diffusive reinforcement signal in the form of extracellular dopamine DA can selectively influence the right synapses at the right time.
Owner:NEUROSCI RES FOUND

Method for preparing nano silver-containing anti-bacterial fabric by immersion process

The invention relates to a method for preparing a nano silver-containing anti-bacterial fabric by an immersion process. The method comprises the following steps: dissolving dopamine hydrochloride in Tris buffer solution; adjusting the pH value of solution to be between 7 and 10 by using hydrochloric acid; immerging a fabric into prepared dopamine solution in a bath ratio of 1:30; after stirring for reacting at the temperature of between 20 and 40 DEG C for 20 to 30 hours, taking the fabric out and washing to obtain a poly dopamine film-coated fabric; putting the fabric into silver nitrate aqueous solution; and after immerging for 8 to 10 hours, washing and drying the fabric to obtain the nano silver-containing fabric. The nano silver-containing fabric prepared by the method has the characteristics of high soaping fastness resistance and lasting antibiotic property; a sterilizing rate is still up to 100 percent after the fabric is washed with water for 30 times; and the preparation method has the characteristics of simple process, no pollution to the environment, low cost and large-scale production.
Owner:DONGHUA UNIV

Methods and compositions for sleep disorders and other disorders

Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and / or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and / or Parkinson's disease or any combinations.
Owner:INTRA CELLULAR THERAPIES INC

Implantable polymeric device for sustained release of dopamine agonist

The present invention provides compositions, methods, and kits for treatment of Parkinson's disease and other conditions for which treatment with a dopamine agonist is therapeutically beneficial. The invention provides a biocompatible nonerodible polymeric device which releases dopamine agonist continuously with generally linear release kinetics for extended periods of time. Dopamine agonist is released through pores that open to the surface of the polymeric matrix in which it is encapsulated. The device may be administered subcutaneously to an individual in need of continuous treatment with dopamine agonist.
Owner:TITAN PHARMA

Solving the distal reward problem through linkage of STDP and dopamine signaling

In Pavlovian and instrumental conditioning, rewards typically come seconds after reward-triggering actions, creating an explanatory conundrum known as the distal reward problem or the credit assignment problem. How does the brain know what firing patterns of what neurons are responsible for the reward if (1) the firing patterns are no longer there when the reward arrives and (2) most neurons and synapses are active during the waiting period to the reward? A model network and computer simulation of cortical spiking neurons with spike-timing-dependent plasticity (STDP) modulated by dopamine (DA) is disclosed to answer this question. STDP is triggered by nearly-coincident firing patterns of a presynaptic neuron and a postsynaptic neuron on a millisecond time scale, with slow kinetics of subsequent synaptic plasticity being sensitive to changes in the extracellular dopamine DA concentration during the critical period of a few seconds after the nearly-coincident firing patterns. Random neuronal firings during the waiting period leading to the reward do not affect STDP, and hence make the neural network insensitive to this ongoing random firing activity. The importance of precise firing patterns in brain dynamics and the use of a global diffusive reinforcement signal in the form of extracellular dopamine DA can selectively influence the right synapses at the right time.
Owner:NEUROSCI RES FOUND

Parenteral formulations of dopamine agonists

InactiveUS20100035886A1Reducing elevated cardiovascular-related inflammatory factorReducing elevated cardiovascular-related inflammatory factorsBiocideMetabolism disorderParenteral nutritionParenteral Dosage Form
This invention relates to stable pharmaceutical compositions for parenteral administration comprising dopamine agonists and peripheral acting agents useful for treatment of metabolic disorders or key elements thereof. The parenteral dosage forms exhibit long stable shelf life and distinct pharmacokinetics.
Owner:VEROSCI

Controlled release delivery system for nasal application of neurotransmitters

This invention relates to a galenical gel formulation for nasal administration of neurotransmitters / neuromodulators such as dopamine, serotonin or pregnenolone and progesterone. The special lipophilic or partly lipophilic system of the invention leads to high bioavailability of the active ingredient in plasma and brain caused by sustained serum levels and / or direct or partly direct transport from nose to the brain.
Owner:MATTERN PHARMA

Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression

One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., insomnia and / or depression. The first component of the pharmaceutical composition is a GABA receptor modulating compound. The second component of the pharmaceutical composition is a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a 5-HT2A modulator, or dopamine reuptake inhibitor. In certain embodiments, the pharmaceutical composition comprises eszopiclone. In a preferred embodiment, the pharmaceutical composition comprises eszopiclone and fluoxetine. The present invention also relates to a method of treating a sleep abnormality, treating insomnia, treating depression, augmenting antidepressant therapy, eliciting a dose-sparing effect, reducing depression relapse, improving the efficacy of antidepressant therapy or improving the tolerability of antidepressant therapy, comprising co-administering to a patient in need thereof a GABA-receptor-modulating compound; and a SRI, NRI, 5-HT2A modulator or DRI.
Owner:SEPACOR INC

Method of in-situ generation of nano particle on separating membrane surface

The invention relates to the technical field of separating membranes, and in particular to a method of in-situ generation of a nano particle on a separating membrane surface. The method comprises the following steps: conducting surface modification on a basic separating membrane surface for more than once, and conducting in-situ generation of the nano particle for more than once on the separating membrane surface subjected to the surface modification, wherein the special points are that the surface modification refers to the following steps: soaking the basic separating membrane in dopamine buffer salt solution with the concentration of 0.001 mg / mL-100 mg / mL and the PH value of 7-12, modifying for 1 min-7 d under the condition that oxygen or oxidant is participated to form a poly-dopamine layer on the basic separating membrane surface; the in-situ generation of the nano particle refers to the following steps: soaking the separating membrane with the poly-dopamine layer generated on the surface in metal salt solution with the concentration of 0,001-10,000 mM / L for 1 min-300 d to generate the nano particle in situ, or accelerating the in-situ generation of the nano particle under the action of reducer. Compared with the prior art, the preparation method is simple and easy to be operated, economic, efficient and environmental-friendly, and facilitates industrialisation.
Owner:山东净泽膜科技有限公司

Polydopamine-based biofunction modification method

The invention discloses a polydopamine-based biofunction modification method. The method comprises the following steps of: soaking clean inorganic / metal materials in dopamine alkaline aqueous solution with a pH value of 7.2 to 10, introducing oxygen to fully oxidize the clean inorganic / metal materials to obtain a monolayer polydopamine modification layer, drying, placing the material in the air atmosphere at 50 to 200 DEG C, performing thermal oxidation to obtain a multi-layer firmly-combined high-reactivity polydopamine layer, and soaking the treated material into the amino-containing and sulfydryl-containing biofunctional molecular solution to obtain a firmly combined biofunction simulate modification layer on the surface of the materials. The polydopamine modification layer obtained bythe method has excellent anti-deformation performance, stability and reactivity, can directly react with amino or the sulfydryl in the biomolecule to immobilize the bioactive molecule on the surface by covalent bonds; moreover, the process is simple, the condition is mild, and the method is easy to implement.
Owner:CO WITH LTD LIABILITY OF MEDICAL SCI +1

Preparation method of hydrophilic antimicrobial film of which surface is coated with dopamine and polyethyleneimine cations

InactiveCN104524986ALong-term hydrophilicLong-lasting antibacterialSemi-permeable membranesPolymer chemistryAntibacterial property
The invention discloses a preparation method of a hydrophilic antimicrobial film of which the surface is coated with dopamine and polyethyleneimine cations. The preparation method comprises the following steps that a base film is prepared, the base film is immersed in a dopamine solution, a polydopamine layer is formed on the surface of the base film by dopamine auto-agglutination, and the polydopamine layer and a polyethyleneimine aqueous solution undergo a reaction so that the hydrophilic antimicrobial film is prepared by the cationization reaction. The preparation method is simple and easy and has mild reaction conditions. The prepared hydrophilic antimicrobial film has excellent hydrophilicity and antibacterial properties, reduces adherence of microbes such as organic matters and bacteria, has a bacterium killing capability and prolongs a film service life.
Owner:NINGBO INST OF MATERIALS TECH & ENG CHINESE ACADEMY OF SCI

Neural stimulation device employing renewable chemical stimulation

A variety of neural stimulation devices are disclosed. The devices comprise an uptake component comprising means for selectively transporting a stimulating species into the device; a release component comprising means for releasing the stimulating species; and means for producing a concentration gradient of a second species. The concentration gradient of the second species provides energy to transport the stimulating species into the device. The stimulating species may be an ion, e.g., a potassium ion, or a neurotransmitter. In a preferred embodiment of the invention the stimulating species is a potassium ion. In a second preferred embodiment the stimulating species is dopamine. In certain embodiments of the invention countertransport across an uptake component comprising a synthetic ABA polymer membrane is achieved using a carboxylic acid crown ether. The gradient of the second species may be provided by means of a chemical reaction that takes place inside the device. The substrate for the chemical reaction is transported into the device from the external environment. In certain embodiments the neural stimulation device comprises light-sensitive elements that comprise light-sensitive proton pumps. The proton pumps translocate protons into the device in response to light, thereby triggering release of the stimulating species. In certain embodiments the neural stimulation device comprises electronic components that receive a signal and send an activating input to the device, thereby triggering release of the stimulating species.
Owner:U S GOVERNMENT REPRESENTED BY THE DEPT OF VETERANS AFFAIRS +2

Method for preparing high-flux composite membrane from dopamine-modified nanometer material

The invention relates to a method for preparing a high-flux composite membrane from a dopamine-modified nanometer material and belongs to the technical field of modification of membrane materials. The method is characterized by comprising the following steps of: forming an active poly-dopamine composite layer on the surfaces of titanium dioxide nanometer grains by utilizing automatic polymerization of dopamine, selecting different concentrations of dopamine-modified titanium dioxide grains, and adding the modified nanometer grains utilized as additives into a membrane casting solution, in which the mass fraction of PVDF (Polyvinylidene Fluoride) is 13% and the mass fraction of PVP (Polyvinyl Pyrrolidone) is 4%, so as to bend and modify according to different proportions, thus obtaining a composite membrane prepared from dopamine-modified nanometer titanium dioxide. The method for preparing the high-flux composite membrane from the dopamine-modified nanometer material, disclosed by the invention, has the advantages that dopamine-modified titanium dioxide can be greatly dispersed in an organic solvent to form a uniform dispersed phase; the additive can be used for effectively improving the hydrophilcity and anti-pollution capability of the high-flux composite membrane; and the dopamine modification method is simple, the condition is gentle, the flux of the prepared membrane is large and the anti-pollution capability is strong.
Owner:DALIAN UNIV OF TECH

Parenteral Formulations of Dopamine Agonists

ActiveUS20090143390A1Reducing elevated cardiovascular-related inflammatory factorReducing elevated cardiovascular-related inflammatory factorsBiocideAntipyreticEnteral administrationParenteral Dosage Form
This invention relates to stable pharmaceutical compositions for parenteral administration comprising dopamine agonists and peripheral acting agents_useful for treatment of metabolic disorders or key elements thereof. The parenteral dosage forms exhibit long stable shelf life and distinct pharmacokinetics.
Owner:VEROSCI

Methods to improve neural outcome

Disclosed herein is a method for protecting dopaminergic neurons of a mammal against death resulting from Parkinson's disease. The method comprises administering a neuroprotective amount of the tripeptide Gly-Pro-Glu.
Owner:NEUREN PHARMA LTD

Differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells by introduction of notch gene

There is provided a method of inducing differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells by introduction of a Notch gene. Specifically, the invention provides a method of inducing differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells in vitro, which method comprises introducing a Notch gene and / or a Notch signaling related gene into the cells, wherein the finally obtained differentiated cells are the result of cell division of the bone marrow stromal cells into which the Notch gene and / or Notch signaling related gene have been introduced. The invention also provides a method of inducing further differentiation of the differentiation-induced neural cells to dopaminergic neurons or acetylcholinergic neurons. The invention yet further provides a treatment method for neurodegenerative and skeletal muscle degenerative diseases which employs neural precursor cells, neural cells or skeletal muscle cells produced by the method of the invention.
Owner:SANBIO

Methods for treating or preventing symptoms of hormonal variations

The present invention relates to methods for treating or preventing symptoms of hormonal variation. The method comprises the steps of administering an effective amount of a receptor antagonist to a subject having one or more symptoms of hormonal variations, wherein the receptor antagonist binds to at least one receptor selected from the group consisting of a serotonin type 2A (5-HT2A) and a dopamine type 2 (D2) receptors.
Owner:YUNG SHIN PHARMACEUTICALS INDUSTRIAL CO LTD

Novel pharmaceutical compositions administering n-0923

The invention relates to a pharmaceutical composition for administering the dopamine agonist N-0923 in depot form. The invention makes available for the first time a depot form of N-0923, which achieves a therapeutically significant plasma level over a period of at least 24 hours after administration to a patient. As a result of poor oral bio-availability and the short plasma half-life, N-0923 was previously administered either by an intravenous drip or by transdermal systems. Preferred embodiments of said invention are oily suspensions, containing the active ingredient N-0923 in a solid phase, in addition to anhydrous pharmaceutical preparations of N-0923.
Owner:UCB SA

Drug treatment for restless leg syndrome

A method for the treatment of Restless Leg Syndrome (RLS), which comprises administering an alpha2-agonist and a second agent selected from the group consisting of the dopamine agonists, opioids, benzodiazepines and the combination of L-DOPA plus a decarboxylase inhibitor.
Owner:BRECHT HANS MICHAEL

Carbostyril derivatives and mood stabilizers for treating mood disorders

The pharmaceutical composition of the present invention comprises a carbostyril derivative which is a dopamine-sero-tonin system stabilizer and a mood stabilizer in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof. The mood stabilizer may include but is not limited to lithium, valproic acid, divalproex sodium, carbamaza-pine, oxcarbamazapine, zonisamide, lamotragine, topiramate, gabapentin, levetiracetam or clonazepam. These compositions are used to treat patients with mood disorders, particularly bipolar disorder with or without psychotic features, mania or mixed episodes. Methods are provided for separate administration of a carbostyril derivative and a mood stabilizer to a patient with a mood disorder.
Owner:OTSUKA PHARM CO LTD

Poly dopamine-modified reduced graphene oxide and preparation method and application thereof

The invention discloses poly dopamine-modified reduced graphene oxide and a preparation method and application thereof, the polydopamine-modified reduced graphene oxide includes reduced graphene oxide and poly dopamine, and the poly dopamine is attached to the surface of the reduced graphene oxide in physical adsorption manner. The preparation method comprises the following steps: according to the mass ratio of (1-4): (1-4), weighing graphene oxide and dopamine hydrochloride, adding the graphene oxide and the dopamine hydrochloride into solvent to completely dissolve to prepare a mixed solution; adjusting the pH value of the mixed solution to 8.5-9, and reacting for 12h-24h at the temperature of 55 to 65 DEG C to obtain the poly dopamine-modified reduced graphene oxide. The preparation method is friendly to the environment, low in reduction temperature, in no need of adding a stabilizer, and simple in process, realizes the reduction and stabilization in one step, and is suitable for mass production. The invention also provides the application of the poly dopamine-modified reduced graphene oxide.
Owner:SHENZHEN INST OF ADVANCED TECH

Method for treating obesity

The present invention relates, in general, to obesity, and, in particular, to a method of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight-loss promoting anticonvulsant either alone or in combination with bupropion or other compound that enhances the activity of norepinephrine and / or dopamine via uptake inhibition or other mechanism.
Owner:DUKE UNIV

Method of inducing differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells by introduction of notch gene

There is provided a method of inducing differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells by introduction of a Notch gene. Specifically, the invention provides a method of inducing differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells in vitro, which method comprises introducing a Notch gene and / or a Notch signaling related gene into the cells, wherein the finally obtained differentiated cells are the result of cell division of the bone marrow stromal cells into which the Notch gene and / or Notch signaling related gene have been introduced. The invention also provides a method of inducing further differentiation of the differentiation-induced neural cells to dopaminergic neurons or acetylcholinergic neurons. The invention yet further provides a treatment method for neurodegenerative and skeletal muscle degenerative diseases which employs neural precursor cells, neural cells or skeletal muscle cells produced by the method of the invention.
Owner:SANBIO

Polymer deposition and modification of membranes for fouling resistance

InactiveUS20100059433A1Reduces biofilm formationStrong adhesionSemi-permeable membranesMembranesBiofilmSolvent
The present invention describes methods and compositions for the reduction, prevention and elimination of biofilm formation on a surface. The present invention provides a method of depositing a coating material to reduce or prevent biofilm formation on a surface by adding a dopamine coating material to a liquid solvent to form a solution mixture, adjusting a pH of the solution mixture to 8, 9, or 10 and dissolving the dopamine coating material in the liquid solvent. The solution mixture is then placed into contact with one or more surfaces to form a dopamine coating on the surface to reduce biofilm formation.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST

Gene specifically expressed in postmitotic dopaminergic neuron precursor cells

A novel gene 65B13 expressed specifically and transiently in dopaminergic neuron precursor cells immediately after cell cycle exit was obtained by the present invention. The cellular expression of 65B13 can be used as an index to select cells that are suitable in terms of their safety, survival rate, and network formation ability, for transplant therapy of neurodegenerative diseases such as Parkinson's disease.
Owner:EISIA R&D MANAGEMENT CO LTD

Method for treating drug and behavioral addictions

ActiveUS20070072899A1Diminishing and eliminating symptomReduce weight lossBiocideNervous disorderWithdrawal syndromeAddictive drugs
The present invention is directed to the use of ibudilast for treating addictions, including drug and behavioral addictions. In particular, ibudilast is used to diminish the dopamine-mediated reward associated with addictions and to treat withdrawal syndromes after discontinuance of addictive drug use or behavior.
Owner:MEDICINOVA INC +1

Method for conducting surface chemical copper plating on inorganic particles through dopamine

The invention discloses a method for conducting surface chemical copper plating on inorganic particles through dopamine. The method comprises the steps that poly-dopamine layers are made to subside on the surfaces of the inorganic particles in an alkaline solution through the oxidative polymerization effect of the dopamine, then by utilizing functional groups of the poly-dopamine layers, and meanwhile under the effect of an additional auxiliary reducing agent of dimethylamine broane (DMAB), copper ions are reduced to pure copper on the surfaces of the inorganic particles, and a continuous and compact metal copper layer is formed. The method is simple to operate, low in equipment requirement and low in cost; the prepared copper-plated inorganic particles have the characteristics of being low in density, good in conductivity and the like; the method can be used for preparing electricity and thermal conductive coatings, electromagnetic shielding paint, wave-absorbing materials and the like.
Owner:SOUTH CHINA UNIV OF TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products